Paolo Di Giorgio

CEO at Angelini Ventures

Judge

Leading Angelini Ventures from 2022 with over 20 years of experience in venture capital, R&D and business development in companies such as Angelini Pharma, Novartis and Merck.

He holds a PhD from Harvard University and an MBA from IE business school.

Currently a board member of Argobio and Extend, an observer board member of Pretzel Therapeutics, Freya, Cour, Nouscom and a member of the investment committee of the Angelini Lumira Bioscience Fund